Skip to main content

Research Repository

Advanced Search

DNA damage repair in breast cancer and its therapeutic implications

Ali, Reem; Rakha, Emad A.; Madhusudan, Srinivasan; Bryant, Helen E.


Reem Ali

Professor of Breast Cancer Pathology

Helen E. Bryant


The DNA damage response (DDR) involves the activation of numerous cellular activities that repair DNA lesions and maintain genomic integrity, and is critical in preventing tumorigenesis. Inherited or acquired mutations in specific genes involved in the DNA damage response, for example the breast cancer susceptibility genes 1/2 (BRCA1/2), phosphatase and tensin homolog (PTEN) and P53 are associated with various subtypes of breast cancer. Such changes can render breast cancer cells particularly sensitive to specific DNA damage response inhibitors, for example BRCA1/2 germline mutated cells are sensitive to poly (ADP-ribose) polymerase (PARP) inhibitors. The aims of this review are to discuss specific DNA damage response defects in breast cancer and to present the current stage of development of various DDR inhibitors (namely PARP, ATM/ATR, DNA-PK, PARG, RECQL5, FEN1 and APE1) for breast cancer mono- and combination therapy.


Ali, R., Rakha, E. A., Madhusudan, S., & Bryant, H. E. (2017). DNA damage repair in breast cancer and its therapeutic implications. Pathology, 49(2), 156-165. doi:10.1016/j.pathol.2016.11.002

Journal Article Type Article
Acceptance Date Nov 2, 2016
Online Publication Date Dec 26, 2016
Publication Date Feb 28, 2017
Deposit Date Nov 21, 2018
Journal Pathology
Print ISSN 0031-3025
Publisher Lippincott, Williams & Wilkins
Peer Reviewed Peer Reviewed
Volume 49
Issue 2
Pages 156-165
Keywords Pathology and Forensic Medicine
Public URL
Publisher URL